Evidence map›Paper›PMID 30528835›Full record

ArticleCancer epidemiology2019

Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: Findings from Texas and national SEER areas.

Shuangshuang Fu, Michael Wang, Ruosha Li, David R Lairson, Bo Zhao, Xianglin L Du

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Shuangshuang FuDepartment of Epidemiology, Human Genetics, and Environmental Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Michael WangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. Electronic address: miwang@mdanderson.org.
Ruosha LiDepartment of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
David R LairsonDepartment of Management Policy and Community Health, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Bo ZhaoDepartment of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Xianglin L DuDepartment of Epidemiology, Human Genetics, and Environmental Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA. Electronic address: Xianglin.L.Du@uth.tmc.edu.
The University of Texas Health Science Center at Houston · USThe University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center · US

Funding

Long-term Benefits & Harms of Antihypertensive Drugs in the Elderly: Up to 22-year Follow-Up of ALLHAT Trial ParticipantsR01AG058971 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DU, XIANGLIN · 2018 to 2021
$1.6M
NIA NIH HHS R01 AG058971
6 · The paper itself

Abstract

backgroundOver the past 20 years, many novel agents and treatment regimens have been developed to treat mantle cell lymphoma (MCL). This study aimed to determine the impact of these new regimens on the survival of MCL patients from 1995 to 2013.

methodsAll newly diagnosed adult MCL patients in the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases were included. Patients were grouped into 4 calendar periods based on the time when new novel agents became available: chemotherapy-only (1995-1998, P1), rituximab + chemotherapy (1999-2004, P2), bortezomib and HyperCVAD (2005-2008, P3), bendamustine and Nordic regimen (2009-2013, P4). Associations between these time periods and survival outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazard regressions.

resultsA total of 7,555 SEER patients and 2,055 TCR patients were identified. All-cause mortality rates decreased significantly from 1995 to 2013 (SEER, P < 0.001; TCR, P = 0.03). Multivariable analysis of SEER data showed that the risk of MCL-specific death decreased significantly over the study period with hazard ratios of 0.82 (P2 vs. P1), 0.66 (P3 vs. P1), and 0.58 (P4 vs. P1) (P < 0.0001). Similar results were observed for TCR data (P < 0.0001). In an analysis stratified by tumor stage, only patients with advanced- stage tumors showed a significantly decreased risk of death in both SEER (P < 0.0001) and TCR (P = 0.002) datasets.

conclusionSurvival outcome for MCL patients improved from 1995 to 2013, especially for patients with advanced-stage tumors, potentially reflecting the impact of the introduction of novel agents and new therapeutic regimens.

Indexed as

Molecular Targeted TherapyAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansLymphoma, Mantle-CellMaleMiddle AgedPrognosisRetrospective StudiesSEER ProgramSurvival RateTime FactorsYoung AdultMantle cell lymphomaNovel agents and new regimensSEERSurvivalTexas

Identifiers

PMID30528835
PMCPMC9064181
OpenAlexW2904208274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.